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Pre-Diabetes, Metabolic Syndrome,
and Cardiovascular Risk
Scott M. Grundy, MD, PHD
Dallas, Texas
Pre-diabetes represents an elevation of plasma glucose above the normal range but below that of clinical diabetes.
Pre-diabetes can be identified as either impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). The latter
is detected by oral glucose tolerance testing. Both IFG and IGT are risk factors for type 2 diabetes, and risk is even
greater when IFG and IGT occur together. Pre-diabetes commonly associates with the metabolic syndrome. Both in
turn are closely associated with obesity. The mechanisms whereby obesity predisposes to pre-diabetes and metabolic
syndrome are incompletely understood but likely have a common metabolic soil. Insulin resistance is a common fac-
tor; systemic inflammation engendered by obesity may be another. Pre-diabetes has only a minor impact on micro-
vascular disease; glucose-lowering drugs can delay conversion to diabetes, but whether in the long run the drug ap-
proach will delay development of microvascular disease is in dispute. To date, the drug approach to prevention of
microvascular disease starting with pre-diabetes has not been evaluated. Pre-diabetes carries some predictive power
for macrovascular disease, but most of this association appears to be mediated through the metabolic syndrome.
The preferred clinical approach to cardiovascular prevention is to treat all the metabolic risk factors. For both pre-
diabetes and metabolic syndrome, the desirable approach is lifestyle intervention, especially weight reduction and
physical activity. When drug therapy is contemplated and when the metabolic syndrome is present, the primary con-
sideration is prevention of cardiovascular disease. The major targets are elevations of cholesterol and blood
pressure. (J Am Coll Cardiol 2012;59:635–43) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.080t
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uThe prevalence of type 2 diabetes is increasing in the United
States and worldwide. Because of many complications and
the high costs of diabetes, its prevention and its complica-
tions demand more attention. The major complications of
diabetes are cardiovascular diseases (CVD)—both micro-
vascular disease and macrovascular disease. The leading risk
factor for type 2 diabetes is a condition called pre-diabetes.
The latter’s predisposition to type 2 diabetes makes it a
potential risk factor for CVD as well. Pre-diabetes moreover
aggregates commonly with other CVD risk factors that
make up the metabolic syndrome.
An ongoing debate is whether pre-diabetes deserves tar-
geted identification and clinical intervention (1). Pre-diabetes
generally is defined by either an elevation of fasting or
post-prandial plasma glucose levels. Elevated hemoglobin A1c,
r glycosylated hemoglobin (HbA1c), which integrates
lasma glucose over time, is promoted by some as another
ndicator of pre-diabetes. This paper will review the patho-
enesis and diagnostic criteria for pre-diabetes, its relation
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hat Is Pre-Diabetes?
he term pre-diabetes has had a checkered history. Alberti
2) states that it was first used to denote abnormalities of
regnancy (e.g., high–birth weight babies, hydramnios) or a
trong family history of type 2 diabetes. However, in 1980,
he World Health Organization (WHO) (3) discarded the
erm largely because many subjects with borderline glucose
evels do not convert to diabetes and because many would be
larmed unnecessarily. These problems still pertain. Yet in
005, the American Diabetes Association (ADA) reintro-
uced pre-diabetes to cover impaired glucose tolerance
IGT) and impaired fasting glucose (IFG) but not other risk
actors for diabetes (4). In 2008, WHO’s diabetes task force
gain repudiated the term and discouraged its use (5).
nstead, they suggested “intermediate hyperglycemia” to
ignify IGT and IFG. The ADA nonetheless continues to
se pre-diabetes and defines it as IFT, IGT, and now, HbA1c
of 5.7% to 6.4% (6).
Any definition of pre-diabetes that is restricted to IGT
and/or IFG fails to include other risk factors for diabetes,
such as, a family history of type 2 diabetes or the metabolic
syndrome. Another telling criticism of the term pre-diabetes
is that the many subjects with either IFG or IGT will not
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this reason, another name might
be preferable. The WHO task
force’s “intermediate hyperglycemia”
so far has not been widely adopted
(5). Another possible name is “bor-
derline diabetes,” but this term is not
currently recommended and has no
formal definition. In this review, the
term pre-diabetes will be used
throughout, but with the recogni-
tion that it is not universally ac-
cepted nor does it always foretell
conversion to diabetes.
Pre-Diabetes as
Intermediate
Hyperglycemia
The ADA previously equated
pre-diabetes with the WHO’s
intermediate hyperglycemia, but
recently added borderline levels
of hemoglobin A1c as another
indicator. The WHO so far has
not done so. The ADA’s 3 indi-
cators can be considered along with their pathogenesis and
clinical significance.
Pathogenesis of intermediate hyperglycemia. Two meta-
bolic defects occur in most patients with type 2 diabetes:
insulin resistance and deficient insulin secretion. Elevated
glucose levels in the intermediate range are caused primarily
by a deficiency in insulin secreted by pancreatic beta cells.
Deficient insulin secretion can result either from a loss of beta
cells or impairment of beta cell function. Both occur in type 2
diabetes (7,8). Similar but less severe defects, especially in
insulin secretion, characterize pre-diabetes (9). Most persons
ith pre-diabetes also are insulin-resistant (9).
mpaired glucose tolerance. Normal fasting plasma glu-
ose is a level of100 mg/dl (5.6 mmol/l) or a 2-h plasma
lucose in response to a 75-g oral glucose tolerance test
OGTT) of140 mg/dl (7.8 mmol/l). IGT is recognized
s an intermediate level of post-prandial glucose that carries
ssentially no risk for microvascular complications (10). It is
iagnosed exclusively by OGTT; the 2-h plasma glucose is
40 to 199 mg/dl (7.8 to 11.0 mmol/l). According to recent
HANES (National Health and Nutrition Examination
urvey) data (11), overall IGT prevalence in U.S. adults
20 years of age is 13.8%. The prevalence rises progres-
ively with age. In the European DECODE (Diabetes
pidemiology: Collaborative Analysis of Diagnostic Crite-
ia in Europe) study, IGT rose from 2.9% in 30- to
9-year-old men to 15.1% in 70- to 79-year-old men (12).
ne disadvantage of testing for IGT is the necessity for
GTT; another is that the results are not highly reproduc-
Abbreviations
and Acronyms
ADA  American Diabetes
Association
CI  confidence interval
CKD  chronic kidney
disease
CVD  cardiovascular
disease(s)
HbA1c  glycosylated
hemoglobin
HDL  high-density
lipoprotein
IFG  impaired fasting
glucose
IGT  impaired glucose
tolerance
LDL  low-density
lipoprotein
OGTT  oral glucose
tolerance test
RR  relative risk
WHO  World Health
Organizationble. Nonetheless, it is a relatively strong, albeit variable, Tredictor of type 2 diabetes (13). A predominant metabolic
haracteristic is insulin resistance in muscle, which exists
long with defective insulin secretion (9). In most Western
ountries, conversion rates for isolated IGT range from
.35% to 6.35% per year (14). In the DPP (Diabetes
revention Program) study, in which IFG also was com-
on, conversion to diabetes was approximately 10% yearly
13,15).
mpaired fasting glucose. IFG was introduced by the
DA in 1997 to classify fasting plasma glucose levels of 110
o 125 mg/dl (6.1 to 7.0 mmol/l) (16). By these criteria, the
stimated U.S. prevalence of IFG in adults20 years of age
as approximately 6.9% (17). In 2003, the ADA changed
ts definition of IFG from a fasting level of 110 to 125 mg/dl
o 100 to 125 mg/dl (18). The rationale for the ADA’s
hange was several-fold. First, glucose levels of 100 to 110
g/dl carry higher risk for diabetes compared with nor-
oglycemia. Second, receiver-operator characteristic analy-
is of several studies found that 100 mg/dl is a threshold
evel of fasting glucose that maximizes sensitivity and
pecificity for predicting diabetes. Third, the expert com-
ittee postulated that reducing the threshold for IFG
ould make the prevalence of IFG and IGT concordant.
owever, the latter did not work out. Prevalence of IFG in
he United States after lowering the threshold jumped from
.9% to 25.7%, which was double the 12.9% for IGT (11).
pplying this percentage to the U.S. population 20 years
f age gave IFG to an estimated 57 million adults (19).
thnic breakdown for IFG prevalence showed 21.1% in
on-Hispanic blacks, 25.1% in non-Hispanic whites, and
6.1% in Mexican Americans. Other populations had sim-
lar increases after this change in IFG definition, for
xample, from 11.8% to 37.6% in Denmark and from 10.6%
o 37.6% in India (5).
There have been 2 major criticisms of the ADA’s change
n definition of pre-diabetes based on fasting glucose levels.
irst, a high proportion of the population becomes “medi-
alized,” and second, persons with fasting glucose levels of
00 to 110 mg/dl convert to diabetes with a lower frequency
han do those with levels of 110 to 125 mg/dl. Regarding
he latter, compared with individuals with fasting levels of
00 to 110 mg/dl, those in the range of 110 to 125 mg/dl
ave a 2- to 6-fold higher risk for developing diabetes (5).
ombined Impaired Glucose Tolerance
nd Impaired Fasting Glucose
ne reason the ADA lowered the threshold for IFG was to
void the need for OGTT to diagnose IGT. This aim did
ot entirely succeed. From 1988 to 1994, among U.S. adults
ged 40 to 74 years, 33.8% had IFG by the revised
efinition, whereas only 15.4% had IGT (19). Only about
% of the population had IGT but not IFG because of
ormal fasting glucose. This latter percentage raises the
uestion whether there is any utility in doing OGTT at all.
wo proposed reasons for OGTT are to identify persons
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February 14, 2012:635–43 Pre-Diabetes in Metabolic Syndromewith undetected diabetes or to find those at very high risk
for diabetes. Persons who have both IGT and IFG plus
etabolic syndrome are at greater risk for conversion to
iabetes than are those with only IGT or IFG (15). Such
ersons may be better candidates for aggressive therapy to
elay onset of diabetes (14).
emoglobin A1c
In 2009, an expert committee organized by the ADA, the
International Diabetes Federation, and the European As-
sociation for the Study of Diabetes (20) recommended that
HbA1c become an alternative to plasma glucose for diag-
osing type 2 diabetes. Advances in the measurement of
bA1c and growing evidence of its association with plasma
lucose underlie this recommendation. The expert commit-
ee listed several advantages of HbA1c testing compared
ith glucose measurements for the diagnosis of diabetes.
bA1c is now better standardized. There is less biologic
variability and pre-analytic instability. HbA1c gives a better
easure of overall glycemic exposure and likely risk for
ong-term complications. There is no need for fasting or
imed samples, and HbA1c is less affected by conditions to
produce perturbations in glucose levels. Moreover, it is a
better guide to clinical management of patients. For these
reasons, it is likely that HbA1c will become a standard
pproach to the diagnosis and clinical management of type
diabetes. For the diagnosis of diabetes, the expert com-
ittee recommended an HbA1c threshold of 6.5%.
Whether HbA1c can also be used to identify pre-diabetes
s an important question. The WHO expert committee
dvised against its use for this purpose, citing lack of
ufficient evidence (5). The ADA/International Diabetes
ederation/European Association for the Study of Diabetes
xpert committee was noncommittal; it speculated on a
ange of 6% to 6.5%, but did not recommend it. The ADA
ecently proposed a pre-diabetes range of 5.7% to 6.4% (6),
hich accords with updated NHANES data (21). Another
tudy (22) suggested that HbA1c might obviate the need for
GTT to identify pre-diabetes. Still another report (23)
howed that there is considerable discordance between
bA1c and fasting glucose levels; it implied that many
ndividuals would be misclassified by HbA1c. However,
because HbA1c is a better indicator of integrated glucose
evels, one can ask whether fasting glucose levels are more
ikely to misclassify a person than HbA1c levels. If pre-
diabetes is going to emerge as an important clinical category
and if HbA1c becomes the primary screening method for
ysglycemia, its use to identify subjects with pre-diabetes
ill have to be seriously considered.
re-Diabetes and the Metabolic Syndrome
n elevated glucose level is one component of the current
onsensus definition of the metabolic syndrome (24,25). Oth-
rs are abdominal obesity, elevated blood pressure, elevated
riglycerides, and reduced high-density lipoprotein (HDL)holesterol. Any 3 of these 5 components confer a diagnosis of
he syndrome. Most individuals with the metabolic syndrome
ave abdominal obesity. Excess adipose tissue releases excess
atty acids and a variety of adipokines that seemingly elicit
etabolic risk factors that predispose to both diabetes and
VD (26) (Fig. 1). To manifest the syndrome in obese
ersons, one must also have metabolic susceptibility; the latter
n turn can be conferred by other factors (e.g., genetics, physical
ctivity, and drugs). Many investigators believe that insulin
esistance mediates all the metabolic risk factors of the meta-
olic syndrome (27). The role of insulin resistance in causing
yperglycemia is well established, but whether insulin resis-
ance per se elicits dyslipidemia and hypertension is uncertain.
egardless, most persons with the metabolic syndrome are
nsulin-resistant (28). Therefore, it is not surprising that
revalence of pre-diabetes and metabolic syndrome overlap—
lthough not precisely. For example, in the nondiabetic pop-
lation over 50 years of age, about twice as many individuals
ave IFG plus metabolic syndrome as have IFG alone (29). A
izable portion of this population also has metabolic syndrome
ithout IFG and vice versa. The overlap of pre-diabetes and
etabolic syndrome in other populations is similar to that of
he United States, where it has been determined (30) (Fig. 2).
Figure 1 Metabolic Pathways Underlying
Pre-Diabetes and Metabolic Syndrome
Most persons with both conditions are obese. An increase in adipose tissue
results in elevations of circulating free fatty acids (FFA) and other “adipokines.”
The latter appear to underlie both a proinflammatory state and a prothrombotic
state. An increase in FFA induces insulin resistance (IR) in muscle, which con-
tributes to an elevation of plasma glucose. In the long run, a high FFA may
impair beta-cell function through “lipotoxicity”; this too will promote a higher
glucose concentration. Elevated FFA probably contributes to an increase in
hepatic glucose output (HGO) and worsening hyperglycemia, but in addition, a
high FFA underlies an increase in plasma triglycerides (TG), which in turn low-
ers high-density lipoprotein (HDL) cholesterol levels. Obesity is associated with
an increase in blood pressure (BP), although the mechanisms for this effect
are not well understood. A proinflammatory state likely predisposes to pre-
diabetes by enhancing IR. Many investigators also believe that a proinflamma-
tory state predisposes to cardiovascular disease, as does a prothrombotic
state. Although obesity predisposes to both pre-diabetes and metabolic syn-
drome, various localized defects in specific organs or tissue likely contribute as
well. Figure illustration by Craig Skaggs.
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Pre-Diabetes in Metabolic Syndrome February 14, 2012:635–43The metabolic syndrome in fact can be considered a
pre-diabetic state. Compared with persons without meta-
bolic syndrome, those with the syndrome have an approxi-
mate 5-fold increase in diabetes risk (31). Although it might
be assumed that this greater risk is due to IFG or IGT in
patients with metabolic syndrome, Lorenzo et al. (32) found
that metabolic syndrome without pre-diabetes carries an
approximate 5-fold increase in diabetes risk. For patients
with IFG or IGT, the diabetes risk is 5- to 7-fold higher for
than normoglycemia (32). However, when pre-diabetes
combines with metabolic syndrome, the risk is increased
even more. We might ask why metabolic syndrome alone is
a strong predictor of diabetes. For one reason, similar
percentages of the population with metabolic syndrome and
pre-diabetes are obese (29); thus, a metabolic syndrome like
pre-diabetes is an insulin-resistant state, which imparts
diabetes risk. The metabolic syndrome may further predis-
pose to beta cell dysfunction through lipotoxicity (33).
Thus, it should not be surprising that the metabolic syn-
drome associates with a high risk for diabetes.
Metabolic Syndrome,
Pre-Diabetes, and Cardiovascular Risk
Should pre-diabetes be called a disease? There is general
agreement among diabetologists that diabetes deserves to be
called a disease and not just a risk factor for CVD. This
agreement rests on the broad range of complications accom-
panying hyperglycemia: macrovascular diseases, microvascu-
lar diseases, and various forms of neuropathy, among others.
Patients with diabetes are prone to coronary heart disease,
stroke, and peripheral vascular disease along with retinop-
athy, chronic kidney disease, bladder dysfunction, erectile
dysfunction, orthostatic hypotension, gastroparesis, and skin
Figure 2 Prevalence of Metabolic Syndrome in Different
Categories of Pre-Diabetes in an European Population
The prevalence in persons with either isolated impaired fasting glucose (IFG) or
impaired glucose tolerance (IGT) was approximately twice that of persons with nei-
ther (30). But in those with both IFG and IGT, approximately three-fourths of the
population had metabolic syndrome. NFG  normoglycemia.disorders. In a variety of ways, these conditions can be Cattributed to prolonged hyperglycemia. Although in the
sense that diabetes is a “risk factor” for these disorders, their
aggregation justifies calling diabetes a disease. To call
pre-diabetes per se a disease is less clear-cut. All of the
preceding complications are less common, although they
have been reported in some patients. A review of available
literature may shed light on the clinical significance of
pre-diabetes.
Pre-diabetes and microvascular disease. A sine qua non
for diabetes contrasted with pre-diabetes is occurrence of
microvascular disease; these diseases include retinopathy,
glomerular disease, and likely neuropathy. The primary
target of hyperglycemia appears to be endothelial cells.
Thickening of the membrane beneath endothelial cells is a
fundamental structural change. This occurs in both capil-
laries and arterioles. Other changes are pericyte loss and
capillary microaneurysms, and later, vascular proliferation.
Although elevated glucose levels per se must be primarily
responsible for microangiopathy, the molecular mechanisms
are not fully understood. Several mechanisms may account
for these changes: activation of protein kinase C, formation
of advanced glycation end products, formation of reactive
oxygen species, flux through the hexosamine pathway,
induction of the polyol pathway, overexpression of growth
factors and inflammatory cytokines, and defective insulin
signaling (34,35). Presumably, these microvascular changes
are widespread throughout the body, but mainly affect the
eyes, kidneys, and peripheral nerves.
The issue of whether intermediate hyperglycemia (pre-
diabetes) can induce diabetic microvascular disease is dis-
cussed in detail in the WHO report of 2006 (5). The
conclusion was that there is no certain plasma glucose
threshold for the development of microangiopathy. Several
reports indicate that in patients with pre-diabetes, “diabetic
retinopathy” can occur (36–39). In Pima Indians, pre-
diabetes was associated with retinopathy in 2% to 4% of
affected subjects (40).
MICROALBUMINURIA. Another putative indicator of micro-
ascular disease is microalbuminuria, which is believed to be
econdary to glomerular endothelial thickening and capillary
eakage (41). Hyperglycemia may be the dominate cause of
lomerular damage, but other factors—advanced glycation
roducts, oxidative stress, and inflammation—have been
mplicated (42). In subjects with pre-diabetes, the preva-
ence of microalbuminuria is approximately twice that of
ormal subjects, but less than that of long-standing diabetes
43). Whether intermediate glycemia per se accounts for an
ncrease in microalbuminuria is uncertain. Microalbumin-
ria has received a great amount of attention because it is
ssociated with both chronic kidney disease (CKD) and
acrovascular disease complications (44). Investigators hy-
othesize that it is a reflection of widespread endothelial
ysfunction.
CHRONIC KIDNEY DISEASE. Diabetes is a major cause of
KD, and pre-diabetes accompanies increased prevalence
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February 14, 2012:635–43 Pre-Diabetes in Metabolic Syndromeof CKD as well. For the NHANES study, Plantinga et al.
(45) reported that 39.6% of people with diagnosed diabetes
and 41.7% with undiagnosed diabetes had CKD; 17.7%
with pre-diabetes and 10.6% without any kind of diabetes
had CKD. The reason for more cases of CKD in pre-
diabetes has not been determined. Microvascular disease
may not be the cause. Fox et al. (46) from the Framingham
Heart Study observed a stronger association between other
cardiovascular risk factors and CKD than with hyperglyce-
mia. This suggests that most of CKD observed in patients
with pre-diabetes is due to macrovascular disease, especially
hypertension, and not to microvascular disease.
NEUROPATHY. Subjects with pre-diabetes can show various
orms of diabetic neuropathy: peripheral neuropathy (47–49),
olyneuropathy (50), small-fiber neuropathy (51), and au-
onomic neuropathy (52,53). In the MONICA (Monitor-
ng Trends and Determinants in Cardiovascular Disease)
tudy, “diabetic” polyneuropathy was approximately twice
hat of normal subjects in those with IFG and IGT, whereas
t was doubled again in patients with diabetes (54). The
europathy observed in patients with diabetes consists of
everal changes: demyelination, axonal thickening, and loss
f nerve fibers. In diabetes, hyperglycemia appears to be the
ominant cause of these changes, and presumably, interme-
iate hyperglycemia can account for more cases of neurop-
thy seen in patients with pre-diabetes.
etabolic syndrome and microvascular disease. Beyond
levated glucose levels, metabolic syndrome generally is
hought not to be related to diabetes-like microvascular
isease. Of note, it is not directly accompanied by “diabetic”
etinopathy (55). If patients with the metabolic syndrome
re found to have retinopathy, it is most likely due to
ntermediate hyperglycemia or hypertensive retinopathy.
ther than these retinopathies, metabolic syndrome may
ediate small vessel disorders through endothelial dysfunc-
ion (56–58). It seems important to distinguish between
tructural damage to small vessels, which occurs with
iabetes and hypertension, and endothelial dysfunction.
he latter can be considered a form of microvascular
isease. For example, the metabolic syndrome has been
elated to microvascular angina (cardiac syndrome X) (59);
his condition may be secondary to endothelial dysfunction
n small coronary arteries (60). Some believe that insulin
esistance is a cause of the endothelial dysfunction of cardiac
yndrome X (61). Other factors, for example, inflammatory
ytokines and low levels of adiponectin, also could promote
ndothelial dysfunction and microvascular dysfunction
62,63). Microalbuminuria is another reflection of endothe-
ial dysfunction and occurs in some persons with the
etabolic syndrome (64–66).
re-diabetes and macrovascular disease. Long unresolved
uestions relate to whether elevated glucose levels are a
irect cause of atherosclerosis or clinical CVD (67–70). If
o, then IFG or IGT could carry some risk for macrovas-
ular disease. Recently Ford et al. (71) carried out a pystematic review of the relationship between pre-diabetes
nd CVD risk. They searched the literature for IFG, IGT,
r both for their relation with CVD. IFG was defined by
asting glucose levels of 100 (or 110) mg/dl to 125 mg/dl
nd IGT was defined by OGTT. The findings of this
eta-analysis can be summarized as follows. Eighteen
eports examined IFG (110 to 125 mg/dl) (designated IFG
10); relative risk (RR) estimates for CVD ranged from
.65 to 2.50. The fixed-effects summary RR was estimated
o be 1.20 (95% confidence interval [CI]: 1.12 to 1.28).
nother 8 reports looked at IFG (100 to 125 mg/dl) (IFG
00). The RRs estimates for individual studies ranged from
.87 to 1.40, whereas the fixed-effects summary RR esti-
ate was 1.18 (95% CI: 1.09 to 1.28). In 8 reports on IGT,
ndividual estimates of RR varied from 0.83 to 1.34, with a
ummary RR estimate of 1.20 (95% CI: 1.07 to 1.34). Five
tudies combined IFG and IGT; the summary RR was 1.10
95% CI: 0.99 to 1.23). There was no significant difference
etween the summary estimates for men and women.
Even if we were to accept this analysis as indicating that
re-diabetes imparts a modest increase in risk for CVD,
uch as in the range of 20%, this does not prove that a
re-diabetic range of glucose levels directly causes athero-
clerosis or its complications. The data are consistent with
his action, but important questions remain. The problem
ies in our ability to dissect away confounding variables such
s concomitant obesity, dyslipidemia, hypertension, and
roinflammatory and prothrombic states. All of the con-
ounding variables listed, which are the components of
etabolic syndrome, are commonly present in persons with
re-diabetes (9).
Of course, if intermediate hyperglycemia independently
oes raise CVD risk by 20%, this would be no trivial matter.
t would justify efforts to lower plasma glucose levels to the
ormal range. Most arguments in the diabetes field have
een whether it is beneficial to lower glucose levels in
atients with pre-diabetes to delay conversion to diabetes.
he argument against drug intervention in pre-diabetes is
hat it may not prevent the development of diabetic micro-
ascular disease in the long run. However, if glucose
oncentrations in this range do in fact raise risk for CVD by
0%, a strong argument can be made to intervene for the
urpose of reducing macrovascular-disease outcomes. The
nly way to resolve this issue would be through a clinical
rial.
One important clinical trial, the DPP (13), tested
hether lifestyle intervention, metformin, or a thiazolidin-
dione will delay conversion of pre-diabetes to diabetes. All
hree effectively lowered glucose levels and retarded the
evelopment of diabetes over the duration of the study
13,72). However, DPP was not sufficiently powered to
etermine whether any of these modalities would reduce
VD events in patients with pre-diabetes. In a subsequent
linical trial using a thiazolidinedione, pioglitazone, to
etermine whether it would reduce CVD events in diabetic
atients with established CVD (73). In fact, atherosclerotic
640 Grundy JACC Vol. 59, No. 7, 2012
Pre-Diabetes in Metabolic Syndrome February 14, 2012:635–43events were marginally reduced, although the benefit was
partially offset by an increase in “heart failure,” that is, fluid
overload. In the DREAM (Diabetes Reduction Assessment
With Ramipril and Rosiglitazone Medication) trial (74),
which was carried out in patients with pre-diabetes, rosigli-
tazone was tested for retardation of conversion to diabetes.
Although this study showed a reduced conversion rate to
diabetes, it did not reduce CVD events. In an ancillary study
to DREAM, however, rosiglitazone modestly reduced pro-
gression of carotid intimal medial thickness (75). This
finding cannot be ignored. It keeps alive the possibility
that glucose lowering in patients with pre-diabetes will
retard atherogenesis. On the other hand, there is the
ongoing controversy whether rosiglitazone will increase
coronary events (76). This being the case, only a clinical
trial with a glucose-lowering drug can answer the ques-
tion whether treatment of intermediate hyperglycemia
will retard atherogenesis.
Most individuals with pre-diabetes have both hyperinsu-
linemia and insulin resistance. It has been speculated for
many years that 1 or another of these finding may promote
atherogenesis (77). If so, it is possible that lowering glucose
through lifestyle changes or drugs that target insulin resis-
tance might reduce atherogenesis through this mechanism.
Metabolic Syndrome and Macrovascular Disease
Two large meta-analysis have shown that metabolic syn-
drome raises the risk for macrovascular CVD by approxi-
mately 2-fold (78,79). Because a high proportion of patients
with metabolic syndrome will have pre-diabetes, it can be
expected that pre-diabetes will also be accompanied by
increased risk for CVD when the metabolic syndrome is
present.
Dual Goals for Pre-Diabetes Intervention
The major detrimental outcomes in persons with pre-
diabetes are macrovascular diseases and type 2 diabetes, the
leading contributors to microvascular disease. Macrovascu-
lar disease occurs both before and after onset of diabetes,
whereas microvascular disease occurs almost exclusively
several years after conversion to diabetes. The following
section provides an overview for prevention of both macro-
vascular and microvascular disease.
Screening for Pre-Diabetes
Should an effort be made to detect pre-diabetes, and if so,
when and how? As desirable as general health screening may
be for prevention of chronic disease, there is little motivation
for a universal national program because of costs. However,
because most people visit physicians periodically, opportunities
exist to test for pre-diabetes. Several clinical features increase
the likelihood of a positive finding: advancing age, obesity,
other features of the metabolic syndrome, family history of
diabetes or CVD, signs of atherosclerotic disease. At thepresent time, we are left with clinical judgment to motivate
testing. Measurement of fasting glucose is the least expensive
way to detect pre-diabetes. OGTT and HbA1c are not cur-
rently recommended, but they can be added if suspicion is
high. Their incremental value has not been adequately studied.
However, the combination of IFG and IGT increases the
likelihood of developing diabetes. In the big picture, preven-
tion of macrovascular disease takes priority over microvascular
disease. Therefore, the first step should be to carry out a
thorough assessment of cardiovascular risk.
Prevention of Macrovascular Disease
Whether pre-diabetes per se produces atherosclerosis and its
complications is uncertain. Nonetheless, many persons with
pre-diabetes have metabolic syndrome, which undoubtedly
is a risk factor for macrovascular disease. Moreover, pre-
diabetes increases with age, and aging itself is accompanied
by increased risk. Therefore, it is reasonable to intensively
intervene on all CVD risk factors in patients with pre-
diabetes. First-line management is lifestyle intervention:
weight reduction in obese subjects, reduced intakes of
dietary saturated and trans-fatty acids, cholesterol, and
sodium, and increased physical activity. The use of drugs to
control CVD risk factors likewise deserves consideration.
Targets of therapy include dyslipidemia, hypertension,
and prothrombotic factors. The prime lipid targets are
atherogenic lipoproteins—low-density lipoprotein (LDL)
and very LDL. In patients with CVD plus metabolic
syndrome, LDL cholesterol levels should be reduced to70
mg/dl, and LDL  very LDL cholesterol (non-HDL
cholesterol) to 100 mg/dl. Statins are first-line drugs to
achieve these reductions. If these goals are not attained with
a statin, a second-line LDL-lowering drug can be used:
nicotinic acid, bile acid sequestrant, or ezetimibe. If CVD is
not present, goals are an LDL cholesterol 100 mg/dl and
a non-HDL cholesterol 130 mg/dl. In most patients, a
statin alone usually is sufficient to achieve this goal.
Blood pressure should be lowered to 130/85 mm Hg,
and preferably to 120/80 mm Hg. Any of the standard
blood pressure–lowering drugs (e.g., angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers, calcium
blockers, diuretics, beta-blockers) can be employed. Evi-
dence favoring 1 drug over another is limited. Nonetheless,
physicians should keep in mind that beta-blockers and
higher doses of thiazide diuretics raise glucose levels and
predispose patients to conversion to diabetes. Opinion is
divided whether these actions have clinical significance in
patients with pre-diabetes (80).
A large clinical trial recently found that aspirin therapy
does not overall reduce CVD events in patients with
diabetes (81). However, this failure appeared to be limited
to persons on hypoglycemic drugs; those on diet-therapy
alone showed risk reduction. This suggests that patients
with early diabetes and almost certainly those with pre-
diabetes will benefit.
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The only way to prevent (or delay) microvascular disease in
patients with pre-diabetes is to prevent (or delay) the
development of diabetes. Unfortunately, there is no proven
way to prevent the decline in beta cell function in persons
destined to have diabetes. Therefore, priority must be given
to reducing insulin resistance. This is best achieved by
lifestyle intervention—weight reduction and increased
physical activity. The DPP (13) demonstrated the efficacy of
this approach. Consequently, all persons with pre-diabetes
should be encouraged to engage in a lifestyle intervention
program. If need be, professional assistance is useful. The
DPP found that metformin therapy also could delay con-
version of pre-diabetes to diabetes in about 40% of subjects.
This has led to a recommendation on the part of some
diabetologists for the use of metformin in persons with IFG
plus IGT and other metabolic syndrome risk factors (15).
Whether this approach will materially retard the develop-
ment of microvascular disease would require a major clinical
trial that is unlikely in the near future.
Public Health Prevention
The public at large is increasingly concerned about the diabetes
epidemic. Most people know relatives or friends who have
diabetes so that they have first-hand knowledge of the suffering
imposed by this chronic disease. Therefore, when a person is
told that he or she has pre-diabetes, this person’s concern is
usually increased substantially. This provides an incentive for
effective intervention. It further offers the opportunity to detect
the metabolic syndrome, which carries greater risk for macro-
vascular CVD. In a word, use of the concept of pre-diabetes
can be a useful tool for intervention to prevent both macro-
vascular and microvascular disease. In the view of this author,
the time is ripe to make use of this concept in clinical and
public health spheres.
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